A phase 2 open-label study to investigate the pharmacodynamics and clinical activity of IPI-504 in patients with castration-resistant prostate cancer stratified by prior chemotherapy
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2012
At a glance
- Drugs Retaspimycin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Infinity Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 14 Jul 2008 Status changed from recruiting to discontinued, as reported in an Infinity Pharmaceuticals media release.